World Health Organization Issues Warning Over Acute Shortage of Weight-Loss Injections
Fewer than one in 10 individuals that would benefit from obesity jabs including Wegovy can access them, caution the global health agency as it issues its inaugural advice on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for increased and just availability to these injectable treatments.
Based on estimates, more than two billion are projected to be living with obesity by 2030 without intervention.
"The new guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key obstacles to broad availability to the jabs that can help people shift significant body mass, says the organization.
Weight-Loss Drug Shortage
Despite the present best projected outlook, the manufacturing of these medications could only cover about 100 million people – under 10% of those who need them, per the health organization.
The advice encourages countries and companies to increase availability, by measures such as licensing agreements.
The intellectual property rights on semaglutide – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026.
The Way Obesity Injections Work
The injections replicate a body's own hormone to delay gastric emptying, curb appetite and boost feelings of fullness so people consume fewer calories.
People typically see weight reduction in the initial weeks of commencing the once-weekly jabs.
Research suggests people may see weight return after a year of stopping the drug, when their usual food cravings return.
Being overweight or obese increases your likelihood for experiencing health problems, including diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts people in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.
